Latest News | Glenmark Acquires Acetylcysteine Injection, Launches in US Market

New Delhi, Mar 3 (PTI) Glenmark Pharmaceuticals Ltd on Monday said it has acquired generic version of Acetylcysteine injection from Aspen Pharma USA Inc for an undisclosed sum and launched the same in the US market.

The acquisition by Glenmark Pharmaceuticals Inc. USA, an arm of the company, of Acetylcysteine Injection is of strength 6 gm/30 mL (200 mg/mL) in single-dose vials, Glenmark Pharmaceuticals said in a statement.

Also Read | PNB SO Recruitment 2025: Registration Begins for 350 Specialist Officer Vacancies From March 3, Know Steps To Apply at pnbindia.in.

Glenmark acquired the ANDA for Acetylcysteine injection, 6 gm/30 ml (200 mg/ml) single-dose vials from Aspen Pharma USA Inc.

The injection is used in the treatment of acetaminophen overdose.

Also Read | 8th Pay Commission: Know How to Calculate Salary Hike as Fitment Factor May Increase Basic Pay by 40-50%.

The company's Acetylcysteine injection, 6 gm/30 mL (200 mg/mL) single-dose vials, can be expected to have the same therapeutic effect as the listed drug product Acetadote Injection, 6 gm/30 mL (200 mg/mL) single-dose vials, of Cumberland Pharmaceuticals Inc, it added.

Commenting on the development, Glenmark President & Business Head, North America, Marc Kikuchi said, "This is a great addition to our injectable portfolio in the US market as we continue to drive growth for the hospital segment."

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)